Introduction:
Leading Pharma company delivered a strong Q3 performance, reporting a 78.1% YoY surge in net profit and a 39.7% rise in revenue. Sequential growth remained steady, reflecting robust demand, operational efficiency, and a solid financial position in the industry.
Share price movement of Suven Pharmaceuticals:
On February 13, 2025, Suven Pharmaceuticals Ltd opened at ₹1,159.95, up 10.91% from its previous close of ₹1,045.70. The stock hit a high of ₹1,167.25 (11.63%) and a low of ₹1,069.15. By 2:13 PM, it traded at ₹1,129.00, rising 7.97%, with a market cap of ₹28,787.48 crore.
Suven Pharmaceuticals Reports Strong Q3 Growth:
Suven Pharmaceuticals Limited reported a strong Q3 performance, with net profit rising 78.1% YoY to ₹83.29 crore from ₹46.75 crore. Sequentially, net profit grew 1.6% over ₹81.98 crore in Q2FY25, reflecting the company’s continued business expansion and operational efficiency.
Revenue from operations surged 39.7% YoY to ₹307.15 crore from ₹219.82 crore, while also posting an 19.2% QoQ growth over ₹257.72 crore in Q2FY25. The steady increase highlights Suven Pharma’s robust demand and improved revenue streams across key business segments.
Total income stood at ₹322.86 crore, marking a 37.9% YoY rise from ₹234.16 crore and a 18.8% QoQ increase over ₹271.84 crore. The company’s financial strength and operational excellence continue to drive consistent growth in the pharmaceutical sector.
Stock performance of Suven Pharmaceuticals for Period of 1 week, 6 months and 1 year:
Suven Pharmaceuticals Ltd witnessed a 10.1% decline over the past week, reflecting short-term volatility. However, its six-month return remains positive at 4.42%. Over the past year, the company has delivered an impressive 60% gain, showcasing strong long-term growth potential.
Also Read: PSU stock jumps after company to acquire 100% stake in Ayana Renewable Power
Shareholding pattern of Suven Pharmaceuticals:
| Dec 2024 | Sep 2024 | Jun 2024 | |
| Promoter | 50.10% | 50.10% | 50.10% |
| FII | 10.80% | 10.70% | 9.80% |
| DII | 16.70% | 17.00% | 17.40% |
| Public | 22.40% | 22.30% | 22.70% |
About Suven Pharmaceuticals:
Suven Pharmaceuticals Ltd (NSE: SUVENPHAR) is a Hyderabad-based CDMO company providing services to global pharmaceutical and fine chemical leaders. It specializes in NCE development, process R&D, and commercial manufacturing, ensuring high-quality products that meet customer needs and expectations.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
